Luis Montuenga, MD, Clinica Universidad de Navarra, Pamplona, Spain, discusses utilizing various molecular biomarkers in screening for lung cancer, including proteins circulating the blood and circulating tumor DNA (ctDNA), which can aid in defining risk levels of patients as low, intermediate, or high-risk. This interview took place during the virtual European Lung Cancer Congress 2022.
